These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33624583)

  • 41. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B; Zareei S; Zareei M
    Immun Inflamm Dis; 2021 Dec; 9(4):1197-1208. PubMed ID: 34347937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19.
    Zhang Z; Wang S; Tu X; Peng X; Huang Y; Wang L; Ju W; Rao J; Li X; Zhu D; Sun H; Chen H
    J Med Virol; 2020 Nov; 92(11):2631-2636. PubMed ID: 32501538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
    Baghaei P; Dastan F; Marjani M; Moniri A; Abtahian Z; Ghadimi S; Valizadeh M; Heshmatnia J; Sadat Mirenayat M; Abedini A; Kiani A; Eslaminejad A; MohammadReza Hashemian S; Jamaati H; Zali A; Akbar Velayati A; Tabarsi P
    Int Immunopharmacol; 2021 Mar; 92():107329. PubMed ID: 33412395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2020 Oct; 396(10259):1345-1352. PubMed ID: 33031764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
    Elmekaty EZI; Alibrahim R; Hassanin R; Eltaib S; Elsayed A; Rustom F; Mohamed Ibrahim MI; Abu Khattab M; Al Soub H; Al Maslamani M; Al-Khal A
    PLoS One; 2022; 17(5):e0267884. PubMed ID: 35507606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
    Singh A
    Ann Intern Med; 2021 Jan; 174(1):JC3. PubMed ID: 33395331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
    Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
    BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.
    Patel TK; Patel PB; Barvaliya M; Saurabh MK; Bhalla HL; Khosla PP
    J Infect Public Health; 2021 Jun; 14(6):740-748. PubMed ID: 34020215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.
    Chouchana L; Boujaafar S; Gana I; Preta LH; Regard L; Legendre P; Azoulay C; Canouï E; Zerbit J; Carlier N; Terrier B; Kernéis S; Batista R; Treluyer JM; Zheng Y; Benaboud S
    Ther Drug Monit; 2021 Feb; 43(1):131-135. PubMed ID: 33230045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
    Arabi YM; Gordon AC; Derde LPG; Nichol AD; Murthy S; Beidh FA; Annane D; Swaidan LA; Beane A; Beasley R; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Buzgau A; Cheng A; De Jong M; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Fowler R; Girard TD; Goligher EC; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Huang DT; King AJ; Lamontagne F; Lawler PR; Lewis R; Linstrum K; Litton E; Lorenzi E; Malakouti S; McAuley DF; McGlothlin A; Mcguinness S; McVerry BJ; Montgomery SK; Morpeth SC; Mouncey PR; Orr K; Parke R; Parker JC; Patanwala AE; Rowan KM; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Tong SYC; Turgeon AF; Turner AM; Van de Veerdonk FL; Zarychanski R; Green C; Berry S; Marshall JC; McArthur C; Angus DC; Webb SA;
    Intensive Care Med; 2021 Aug; 47(8):867-886. PubMed ID: 34251506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
    Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
    Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment strategies of hospitalized patients with coronavirus disease-19.
    Huang Y; Cai C; Zang J; Xie J; Xu D; Zheng F; Zhan T; Huang K; Wang Y; Wang X; Hu ZY; Deng Y; Xie Y
    Aging (Albany NY); 2020 Jun; 12(12):11224-11237. PubMed ID: 32554861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.
    Guo YZ; Xu KJ; Li YT; Fu JD; Xu M; Yu L; Sheng JF; Zhu B
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):948-954. PubMed ID: 33843160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.
    Hariyanto TI; Kristine E; Jillian Hardi C; Kurniawan A
    Infect Disord Drug Targets; 2021; 21(5):e270421187364. PubMed ID: 33121422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
    Ye XT; Luo YL; Xia SC; Sun QF; Ding JG; Zhou Y; Chen W; Wang XF; Zhang WW; Du WJ; Ruan ZW; Hong L
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3390-3396. PubMed ID: 32271456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
    Xie X; Jiang Y; Zeng Y; Liu H
    Antivir Ther; 2020; 25(4):233-239. PubMed ID: 32496210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
    Amani B; Khanijahani A; Amani B; Hashemi P
    J Pharm Pharm Sci; 2021; 24():246-257. PubMed ID: 34048671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.